Nucynta is owned by Collegium Pharm Inc.
Nucynta contains Tapentadol Hydrochloride.
Nucynta has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Nucynta are:
Nucynta was authorised for market use on 15 October, 2012.
Nucynta is available in solution;oral dosage forms.
Nucynta can be used as relief of moderate to severe acute pain.
The generics of Nucynta are possible to be released after 27 June, 2025.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|USRE39593||COLLEGIUM PHARM INC||1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects|| |
(7 months ago)
|US7994364||COLLEGIUM PHARM INC||Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride|| |
(2 years from now)
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2012
Treatment: Relief of moderate to severe acute pain
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic